home
Author : adminDate : 2022-04-29 10:00

Elevar Therapeutics to announce Phase 2 Results of Rivoceranib on ACC at ASCO

Elevar Therapeutics will announce the results of phase 2 Rivoceranib clinical trials for Adenoid Cystic Carcinoma (ACC) at the 2022 American Society of Clinical Oncology Annual Meeting (2022 ASCO).

 

The following clinical trial was conducted on 72 patients with recurrent or metastatic ACC in South Korea and the United States. Elevar will operate a separate booth (#28089) during the meeting and introduce various pipelines and efficacy of Rivoceranib to clinicians and multinational pharmaceutical companies around the world.

 

ACC is a rare disease that occurs more than 1,200 patients every year in the United States alone. Until now, it has been an intractable disease with no suitable treatments other than repetitive surgery or radioactive treatment. Rivoceranib, designated as an orphan drug by the FDA in February last year, is likely to receive New Drug Application (NDA) approval without phase 3 clinical trials.

 

Elevar began administering the first patient in March 2020. Initially, it aimed to recruit 55 patients, but expanded it to 72  at the request of specialists and patients. The clinical trials were conducted at seven organizations, including the University of California, San Francisco (UCSF), Dana-Farber Cancer Institute, and the University of Michigan, as well as Korean institutions such as Seoul National University Hospital, Asian Medical Center, Samsung Medical Center, and National Cancer Center. The primary endpoint was Overall Response Rate (ORR), and the secondary endpoint was Overall Survival (OS), Progression-Free Survival (PFS), and Disease Control Rate (DCR).

 

The development of first line ACC treatment is one of the most important treatments for HLB in Korea, which has vowed to proceed with two cases of NDA within a year.    

In addition to ACC, the third phase of global clinical trials for Hepatocellular Carcinoma (HCC),  undergoing combination therapy with Rivoceranib and Camrelizumab (PD-1 inhibition), are also expected to end this year.

 

In-Keun Jang, Vice-President of HLB’s Bio Strategic Planning Team said, "In addition to the presentation at ASCO, hundreds of papers demonstrate the superior efficacy and safety of Rivoceranib for various cancers in succession” and said, “for many patients who are suffering from lack of proper treatment and looking forward to an innovative new drug, we will do our best to get accelerated approval from FDA”.

He also added “the announcement at ASCO will mark the most important milestone for HLB to become a global pharmaceutical company”.